Understanding how lung cells respond to mechanical signals in fibrosis
Mechanosensing in lung fibrosis
['FUNDING_R01'] · GEORGIA INSTITUTE OF TECHNOLOGY · NIH-10944346
This study is looking at how aging affects lung cells in people with idiopathic pulmonary fibrosis (IPF) and testing a new way to deliver treatments that might help reduce lung scarring.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGIA INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10944346 on ClinicalTrials.gov |
What this research studies
This research investigates the role of mechanosensing in idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by scarring and difficulty in breathing. The study aims to understand how aging affects the behavior of lung cells, particularly fibroblasts, in response to mechanical signals from their environment. Using a 3D bioengineered model that simulates lung tissue, researchers will explore how these cells contribute to fibrosis and test the effectiveness of inhaled microparticles that deliver specific inhibitors to reduce lung scarring. This approach could lead to new therapeutic strategies for managing IPF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis, particularly those who are older and may have age-related factors influencing their condition.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that slow down or reverse lung fibrosis, improving the quality of life for patients with IPF.
How similar studies have performed: Previous research has shown promising results in understanding mechanosensing in other fibrotic diseases, suggesting that this approach may yield valuable insights and potential breakthroughs in treating IPF.
Where this research is happening
ATLANTA, UNITED STATES
- GEORGIA INSTITUTE OF TECHNOLOGY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARCIA, ANDRES J — GEORGIA INSTITUTE OF TECHNOLOGY
- Study coordinator: GARCIA, ANDRES J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.